#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4588	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2302	393.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1843	1843	T	497	T,C,G	316,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4588	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2302	393.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1577	1577	C	544	C,G	353,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	8664	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3801	436.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1948	1948	A	486	A	323	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	8664	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3801	436.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2582	2582	C	478	C,T,A	309,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	8664	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3801	436.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2656	2656	A	503	A	323	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	8664	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3801	436.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3208	3208	C	520	C	341	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	8664	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3801	436.4	0	HET	.	.	.	C2212T	.	2212	2212	C	2823	2823	C	523	C,T	269,62	.	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	342	folP	855	855	100.0	folP.l6.c4.ctg.1	1579	43.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1028	1030	AGC	67;67;67	A;G;C	47;47;47	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	962	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3637	52.4	1	SNP	p	S91F	1	.	.	271	273	TTC	725	727	TTC	51;51;51	T;T;C	36;36;37	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	962	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3637	52.4	1	SNP	p	D95G	1	.	.	283	285	GGC	737	739	GGC	56;57;57	G;G;C	40;39;39	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	962	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3637	52.4	1	SNP	p	G95N	0	.	.	283	285	GGC	737	739	GGC	56;57;57	G;G;C	40;39;39	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	302	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1201	52.4	1	SNP	p	G45D	0	.	.	133	135	GGC	386	388	GGC	96;96;96	G;G;C	58;58;59	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	218	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	969	42.5	0	.	n	.	0	A197.	DEL	197	197	A	535	535	A	104	A	68	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	740	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3092	46.9	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1392	1394	GTC	56;54;54	G;T;C	34;34;34	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	740	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3092	46.9	1	SNP	p	D86N	0	.	.	256	258	GAC	498	500	GAC	66;66;67	G;A;C,A	43;38;43,1	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	740	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3092	46.9	1	SNP	p	R87W	0	.	.	259	261	CGT	501	503	CGT	67;67;71	C;G;T,G	47;43;48,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	740	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3092	46.9	1	SNP	p	S87R	1	.	.	259	261	CGT	501	503	CGT	67;67;71	C;G;T,G	47;43;48,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	740	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3092	46.9	1	SNP	p	R87I	0	.	.	259	261	CGT	501	503	CGT	67;67;71	C;G;T,G	47;43;48,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	740	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3092	46.9	1	SNP	p	S88P	0	.	.	262	264	TCC	504	506	TCC	71;71;71	T;C;C	48;51;49	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	706	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2754	49.7	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1341	1343	TGC	56;56;55	T;G;C	36;38;35	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	706	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2754	49.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1551	1553	GGC	40;40;40	G;G;C	30;29;30	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1044	1046	GCA	133;135;133	G;C;A	85;87;86	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1047	1049	ATC	133;133;133	A,C;T;C	85,1;86;85	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1059	1061	GTG	136;138;139	G;T;G	88;88;89	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1059	1061	GTG	136;138;139	G;T;G	88;88;89	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1563	1565	ACC	63;63;63	A;C;C	38;42;45	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1617	1619	GCG	53;55;55	G;C;G	36;37;39	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1617	1619	GCG	53;55;55	G;C;G	36;37;39	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1740	1742	GGC	46;46;46	G,A,T,C;G;C	34,1,1,1;37;38	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1749	1751	GGC	43;43;43	G,C;G;C	31,3;32;31	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	908	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2044	83.0	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1767	1769	TCG	40;40;40	T,C,G;C,T;G,C	20,1,1;25,1;24,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	1602	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3548	84.6	0	.	p	.	0	E418G	NONSYN	1252	1254	GAG	1841	1843	GGG	79;83;80	G;G;G	56;60;56	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	1602	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3548	84.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1850	1852	CCG	78;75;75	C;C;G,T	56;53;51,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	522	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2149	47.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	857	857	C	50	C	32	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	561	563	GAA	94;89;89	G,A;A;A	66,1;64;64	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	849	851	GAT	83;90;90	G,A;A;T	63,1;65;65	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	972	974	TCA	88;88;88	T,C;C;A	57,1;57;58	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1101	1103	GTC	80;85;85	G;T;C	54;56;54	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1431	1433	GCA	75;75;71	G;C;A	50;50;49	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	1	SNP	p	G120K	1	.	.	358	360	AAG	807	809	AAG	88;88;87	A;A;G,T	66;66;65,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	1	SNP	p	A121D	1	.	.	361	363	GAC	810	812	GAC	89;89;87	G;A;C	68;68;67	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	556	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1792	64.4	1	SNP	p	D121N	0	.	.	361	363	GAC	810	812	GAC	89;89;87	G;A;C	68;68;67	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2322	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4938	92.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1838	1840	AAT	121;120;120	A;A;T	77;77;77	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	232	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1298	37.4	1	SNP	p	V57M	1	.	.	169	171	ATG	656	658	ATG	85;85;90	A;T;G	53;54;57	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
